Key Drivers
- Cash Generation
- Leverage Pressure
- Weak Liquidity
AIAI Summary
AHCO's refinancing to 2031 and strong organic growth shift the story from balance-sheet survival to proving it can convert record patient census and revenue momentum into durable EBITDA and free cash flow, but rising labor/capex costs and sub-1x interest coverage mean investors should wait for margin and cash-flow proof before re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Leverage Pressure
- •Weak Liquidity
AHCO still generates solid operating cash and trades at a low sales/book valuation, but weak earnings, heavy interest burden, and tightening liquidity make the balance sheet and profitability risk the main concerns.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support hold
- •Reclaim needed
AHCO is in a clear downtrend over the last month, with lower highs/lower lows after breaking $11.25–$11.30, but holding $10.60–$10.66 could stabilize the selloff while a reclaim of $11.25+ is needed to improve the setup.
Briefly rallied to $13.17 on 2026-05-04 before a sharp breakdown from $11.25–$11.30
Sentiment & News
Key News Insights:
- •Organic growth
- •Labor pressure
- •De novo expansion
AdaptHealth reported Q1 2026 results with broad organic growth and the largest de novo expansion in home medical equipment, but higher labor costs from a capitated contract transition pressured EBITDA.
The update is mildly positive on growth but likely neutral-to-negative for near-term margin and earnings sentiment due to cost pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings